Trials / Completed
CompletedNCT01187628
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
An Open-label, Long-term Extension Study of Lanthanum Carbonate 750 to 2,250 mg in Hyperphosphatemia in Patients With Chronic Kidney Disease Not on Dialysis (52 Weeks Extension From Study 14817)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the safety and the effect on reduction of serum phosphate of long-term administration of lanthanum carbonate (BAY77-1931) 750 to 2250 mg in patients with hyperphosphatemia who completed the 8 week double-blind treatment period of Study 14817 and are judged to be eligible for the long-term extension study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fosrenol (Lanthanum Carbonate, BAY77-1931) | Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks. |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2010-08-24
- Last updated
- 2015-04-03
Locations
40 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01187628. Inclusion in this directory is not an endorsement.